Market revenue in 2023 | USD 6,349.5 million |
Market revenue in 2030 | USD 10,998.7 million |
Growth rate | 8.2% (CAGR from 2023 to 2030) |
Largest segment | Next generation sequencing |
Fastest growing segment | Next Generation Sequencing |
Historical data covered | 2018 - 2022 |
Base year for estimation | 2023 |
Forecast period covered | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Next Generation Sequencing, QPCR & Multiplexing, LOAC & RT-PCR, Protein Microarrays, DNA Microarrays |
Key market players worldwide | Johnson & Johnson, Illumina Inc, Novartis AG ADR, Roche, Koninklijke Philips NV, Qiagen NV, Agilent Technologies Inc, Abbott Laboratories, Thermo Fisher Scientific Inc, GE HealthCare Technologies Inc Common Stock |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to next generation cancer diagnostics market will help companies and investors design strategic landscapes.
Next generation sequencing was the largest segment with a revenue share of 36.98% in 2023. Horizon Databook has segmented the North America next generation cancer diagnostics market based on next generation sequencing, qpcr & multiplexing, loac & rt-pcr, protein microarrays, dna microarrays covering the revenue growth of each sub-segment from 2018 to 2030.
North America market encompasses of U.S. and Canada. The prominent drivers of the market are increased awareness and improved health care facilities for cancer therapeutics and diagnostics.
Constant technological developments followed by new discoveries of specific antigens and biomarkers are responsible for estimated growth of next generation cancer diagnostics market.
North America is leading with an incidence rate of 315.62 estimated cases per 100,000 of adults in 2012, and around 1,786,369 cases in total are expected to grow over the forecast period of 2016 to 2024.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America next generation cancer diagnostics market , including forecasts for subscribers. This continent databook contains high-level insights into North America next generation cancer diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account